SOLID TUMORS

This study tests a personalized vaccine made from your tumor's unique mutations. It aims to train your immune system to attack cancer cells. The trial includes 10 adults with advanced or high-risk solid tumors. Participants receive the vaccine plus immune-boosting drugs over seve…

This study tests the safety and effectiveness of ponatinib in children aged 1 to under 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if the drug can shrink or control the cancer. About 70 childr…

This early-phase trial tests a new oral drug, Aza-TdC, in adults with advanced solid tumors that have not responded to standard treatments. The drug aims to 'turn back on' genes that may slow tumor growth. The main goals are to check the drug's safety and find the best dose.

This early-phase study tests a new drug called HDM2017 in 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug and are…

This study tests an experimental drug called JAB-30355 in adults with advanced solid tumors that have a specific mutation in the TP53 gene (Y220C). The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 144 participants will receive the drug, and research…

This study tests a new drug called 7MW4911 in 200 Chinese patients with advanced solid tumors that have worsened after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow disease progression. Participants must…

This study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a powerful chemotherapy directly to cancer cells. The goal is to see if it can shr…

This early-phase study tests a new radioactive drug called Lutetium BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. Participants must have measurabl…

This early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…

This early-stage study tests a new oral drug, TYRA-430, in people with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. About 100 adults will take part, and the st…

This early-phase trial tests a new treatment made from donor cord blood cells that are engineered to target a protein called TROP2 found on many solid tumors. The goal is to find a safe dose and see how well patients tolerate it. The study enrolls adults with advanced solid tumor…

This study tests a new drug called JR8603 in people with advanced solid tumors (like stomach or colorectal cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 94 adults will take part in this ear…

This early-phase study tests a new treatment called TX103 CAR-T cells in 85 adults with advanced solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target a protein (B7-H3) on cancer cells. The main goals are to …

This early-stage trial tests a new drug, XB371, in about 150 people whose solid tumors have spread or come back. The main goal is to check the drug's safety and find the right dose. Participants must be in fairly good health and have a life expectancy of at least 12 weeks.

This early-stage trial tests an experimental drug called QTX3034, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety, find the right dose, and see if the drug can sh…

This early-phase study tests a new oral drug, DPTX3186, in 40 adults with advanced solid tumors that have a specific genetic change (Wnt pathway activation) and no other treatment options. The main goals are to check safety, how the drug moves through the body, and to look for ea…

This early-phase study tests a new drug, BI 1831169, in adults with advanced solid tumors that cannot be removed by surgery. The drug is given alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it can shrink tumors. About 190 participants wil…

This study tests a new drug called S-531011, alone or with other cancer treatments, in people with advanced solid tumors that have stopped responding to standard therapies. The goal is to find a safe dose and see if it can shrink tumors or slow cancer growth. About 282 adults wil…

This early-phase study tests a new cell treatment called GK01, given alone or with chemotherapy, for people with advanced solid tumors (like pancreatic or stomach cancer). The main goal is to check safety and how the body handles the treatment. Only 15 participants will be enroll…

This study tests a new drug called BG-C0902 for people with advanced solid tumors that have not responded to other treatments. The drug is designed to attach to specific proteins on cancer cells and deliver a chemotherapy-like payload directly to them. The main goals are to check…

This early-stage study tests a new drug called HS-20110 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 475 adults will take part in this study a…

This early-phase study tests a new drug, BI 3923948, in adults with advanced solid tumors that have spread and are hard to treat. The drug is given alone or with an immunotherapy (checkpoint inhibitor) to find a safe dose and see if it can shrink tumors. About 60 participants wil…

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good organ function may join.

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in people with solid tumors. The goal is to find a safe dose and see if the combination shrinks tumors. About 100 adults aged 18 to 75 with good performance status are being recruited.

This early-phase study tests a new drug called DCSZ11 alongside standard treatments in 9 adults with advanced or metastatic solid tumors, including head and neck cancer. The goal is to see if the combination is safe and helps shrink or control tumors. Participants must have stand…

This early-phase study tests a new drug called INCB161734, alone or with other cancer therapies, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 710 adults whose cancer ha…

This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in about 76 people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the safest dose and see if the combination can …

This study gives people with solid tumors continued access to the drugs encorafenib and/or binimetinib if they were already benefiting from them in an earlier study. Participants will receive the same dose for up to about 5 years, while doctors monitor safety. Only those currentl…

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo, and researchers will measure urine markers of kidne…

This early-phase study tests a new drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. Participants must have specific canc…

This study tests an experimental drug called ZL-1310 in about 112 adults with advanced neuroendocrine carcinomas that have worsened after standard chemotherapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants will receive the drug and …

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-stage study tests a new drug called HRS-6208 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. About 206 adults a…

This early-phase study tests an experimental drug called INCB123667, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapy. The main goals are to check safety, find the right dose, and see if the drug can help cont…

This study tests a new drug called SOA101, a tri-specific antibody designed to help the immune system attack cancer cells. It is for people with advanced solid tumors (lung, ovarian, head and neck, breast, or colorectal cancer) who have no other treatment options. The trial has t…

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This study follows about 3,500 adults with solid tumors or blood cancers who are already taking or have taken pembrolizumab in earlier trials. Researchers will track long-term safety and how well the drug controls the disease over time. Participants may continue treatment or be m…

This early-stage trial tests a new drug called DS3610a in 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. This is a first-in-human study, so it focuses o…

This study tests whether adding the experimental drug INCB161734 to standard chemotherapy helps people with a specific genetic form of advanced pancreatic cancer (KRAS G12D mutation) live longer and keep their cancer from growing. About 588 participants who have not had prior tre…

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can shrink tumors in people with advanced solid tumors like lung, kidney, or liver cancer. About 170 adults whose cancer has worsened after standard treatments will receive the drug combination. The go…

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; then refining that dose; and finally, checking how well the drug works in a specific canc…

This early-phase study tests a new drug, BL-M24D1, in people with advanced digestive tract or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 33 adults will take part in this non-randomized tr…

This early-phase study tests a radioactive drug called Lutetium-177 BL-ARC001 in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 22 par…

This study tests a new drug called ABL103 combined with pembrolizumab, with or without a chemotherapy drug (taxane), in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About 65 …

This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older with advanced solid tumors or brain tumors that have specific BRAF gene changes. The goal is to see if the drug can shrink tumors and control the disease. About 254 participants will take the drug …

This study tests an experimental drug called ICP-723 in people with advanced solid tumors that cannot be removed by surgery. It includes both adults (18+) and adolescents (12-17). The main goals are to check safety, find the best dose, and see how the drug affects tumors. About 3…

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…

This study tests a new treatment called B7H3 CAR-T cell therapy for people with advanced solid tumors that have a specific marker (B7H3). The therapy uses a patient's own immune cells, modified to better find and attack cancer cells. The main goals are to check safety and see if …

This study tests a new drug called JAB-2485 in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. The trial is in early …

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in adults with advanced or metastatic solid tumors that have not responded to prior treatments. About 492 participants will receive the drugs to see if tumors shrink and to check for side effects. The goa…

This study tests a new drug called SHR-4610 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding the safest dose, then checking if it shrinks tumors or slows their growth. About 258 adults aged 18-75 wit…

This early-stage study tests a new drug called AUBE00 in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have a …

This early-phase study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find the highest safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703…

This early-phase study tests a new drug called AB521 (casdatifan) in people with advanced kidney cancer or other solid tumors that have not responded to standard treatments. The study will first find a safe dose of AB521 alone, then test it alone or combined with other cancer dru…

This early-phase study tests a new drug called CBA-1205, an antibody that targets a protein (DLK1) found on some cancer cells. The main goal is to check safety and find the right dose in about 66 adults with advanced solid tumors, including liver cancer and melanoma. Participants…

This early-stage study is testing a new experimental drug called ZL-6201 in adults with advanced sarcoma and other solid tumors that have spread or cannot be removed by surgery. The main goal is to find a safe dose and understand how the body processes the drug, while also lookin…

This early-stage study is testing a new radioactive tracer called RT01-89Zr that attaches to a protein found on many solid tumors. The goal is to see if it is safe and can make tumors show up more clearly on PET/CT scans. Ten adults with confirmed solid tumors will receive the tr…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The goal is to see if it safely helps their white blood cell counts recover faster, reducing the risk of serious infections. Participants will be monitored fo…

This study aims to find a way to predict serious side effects from cancer immunotherapy. Researchers will measure substances called interferons in the blood of 300 cancer patients starting immunotherapy and 40 people with autoimmune diseases like lupus. By comparing these groups,…

This study looks at gene changes (mutations) in tumors from people with cancer or those being checked for cancer. Researchers use leftover tissue from past surgeries or biopsies, plus a blood or saliva sample, to compare normal and cancer genes. The goal is to learn which mutatio…

This study is building a large registry of 15,000 people who received radiation therapy for cancer at Mayo Clinic. Researchers will collect medical information and biological samples to see how treatment affects side effects, quality of life, and survival. The goal is to learn fr…

This study is testing a new combination of two drugs (SAR444881 and cemiplimab) in people with certain solid tumors, including lung, colorectal, and ovarian cancers. The main goal is to find biological markers that show how the drugs work, not to cure the disease. About 40 adults…

This study is tracking the safety and effectiveness of a device called RenovoCath, which delivers chemotherapy drugs directly to solid tumors through a blood vessel. Researchers will follow 1,000 adult cancer patients who receive this treatment in real-world settings. The goal is…